Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2025 12:02 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses...
June 12, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior...
June 05, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1,...
May 29, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Participation in June Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....
May 14, 2025 09:30 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab...
May 12, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - ...
May 08, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Participation in May Investor Conferences

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....
May 07, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall...
May 05, 2025 16:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of...
May 02, 2025 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1,...